A Phase 3 interventional study of Atenolol and Hydrochlorothiazide (HCTZ)) in Hypertension, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-06-06.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing atenolol in Hypertension — none open to participants now, none under way, none of them phase 3. Atenolol · Hypertension.
Among the 19 studies testing atenolol in Hypertension, this one is the 16th largest by enrollment, is one of 3 that started in 2005, is the only one in phase 3, and was the 9th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 19 studies testing atenolol in Hypertension is open now. The open studies under Hypertension, anywhere →
Atenolol: first FDA approval 1981 (TENORMIN). What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 64 across the 19 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 210th largest by enrollment of the 223 interventional ones that give a count, is one of 28 that started in 2005, is one of 108 in phase 3, and was the 97th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing atenolol in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.
Drug: Atenolol · Drug: Hydrochlorothiazide (HCTZ)) · Drug: Valsartan
After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning.
Drug: Atenolol · Drug: Hydrochlorothiazide (HCTZ)) · Drug: Valsartan
100 mg tablets orally once a day (od) in the morning.
12.5 or 25 mg tablets orally once a day (od) in the morning.
80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites
10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
Time frame: At end of each treatment period (Week 21 and Week 43)
Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites
10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) plus 10 µl L-NMMA (10-6 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
Time frame: At end of each treatment period (Week 21 and Week 43)
Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites
10 µl of sodium nitroprusside at a concentration of 10-7 M was injected intra-dermally at 1 site on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated and compared to the sodium nitroprusside mean. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
Time frame: At end of each treatment period (Week 21 and Week 43)
Mean Post-treatment Microcirculation at NaCl Injected Sites
10 µl of NaCl was injected intra-dermally at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
Time frame: At end of each treatment period (Week 21 and Week 43)
Arterial Pressure Waveform Augmentation Index at the End of Treatment
Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. The augmentation index is the ratio of the first and second systolic peaks and is used as a surrogate measure of arterial stiffness.
Time frame: At end of each treatment period (Week 21 and Week 43)
Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment
Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. Pulse wave velocity is the speed of the forward traveling wave and can be used as a measure of arterial stiffness since the more rigid the wall of the artery, the faster the wave moves.
Time frame: At end of each treatment period (Week 21 and Week 43)
| Milestone | Valsartan Followed by Atenolol + Hydrochlorothiazide (HCTZ) | Atenolol + Hydrochlorothiazide (HCTZ) Followed by Valsartan |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 13 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | Valsartan Followed by Atenolol + Hydrochlorothiazide (HCTZ) | Atenolol + Hydrochlorothiazide (HCTZ) Followed by Valsartan |
|---|---|---|
| Started | 15 | 13 |
| Completed | 15 | 12 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
| Perfusion units | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites | 61.21 ± 38.11 | 61.04 ± 49.16 |
10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) plus 10 µl L-NMMA (10-6 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
| Perfusion units | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites | -9.11 ± 22.19 | -5.60 ± 40.47 |
10 µl of sodium nitroprusside at a concentration of 10-7 M was injected intra-dermally at 1 site on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated and compared to the sodium nitroprusside mean. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
| Perfusion units | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites | 120.65 ± 74.52 | 128.14 ± 63.79 |
10 µl of NaCl was injected intra-dermally at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
| Perfusion units | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| Mean Post-treatment Microcirculation at NaCl Injected Sites | 44.78 ± 47.53 | 50.96 ± 67.88 |
Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. The augmentation index is the ratio of the first and second systolic peaks and is used as a surrogate measure of arterial stiffness.
| Ratio | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| Arterial Pressure Waveform Augmentation Index at the End of Treatment | 139.05 ± 20.64 | 144.51 ± 21.97 |
Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. Pulse wave velocity is the speed of the forward traveling wave and can be used as a measure of arterial stiffness since the more rigid the wall of the artery, the faster the wave moves.
| Meters per second | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment | 8.07 ± 1.28 | 7.60 ± 1.18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan | — | 0/28 (0%) | 16/28 (57.1%) |
| Atenolol + Hydrochlorothiazide | — | 1/30 (3.3%) | 12/30 (40%) |
| Event | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| DiverticulitisInfections and infestations | 0/28 | 1/30 |
| Event | Valsartan | Atenolol + Hydrochlorothiazide |
|---|---|---|
| HeadacheNervous system disorders | 3/28 | 6/30 |
| VertigoEar and labyrinth disorders | 3/28 | 2/30 |
| BronchitisInfections and infestations | 2/28 | 1/30 |
| CystitisInfections and infestations | 2/28 | 1/30 |
| SinusitisInfections and infestations | 2/28 | 1/30 |
| Upper respiratory tract infectionInfections and infestations | 2/28 | 1/30 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/28 | 0/30 |
| HypotensionVascular disorders | 2/28 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 1/28 | 2/30 |
| Chest painGeneral disorders | 0/28 | 2/30 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 52.3 ± 7.2 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 11 |
| Male | 19 |
The record gives a start of Dec 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atenolol · Hydrochlorothiazide · Valsartan